Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1982 • ACR Convergence 2020
Quality of Life of Patients with Facial Cutaneous Lupus Erythematosus
Josef Symon Concha¹, Daisy Yan¹, Christina Bax², Adarsh Ravishankar³, Robert Borucki⁴, Rui Feng⁴ and Victoria Werth⁵, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²University of Pennsylvania, Department of Dermatology, Philadelphia, ³University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, ⁴University of Pennsylvania, Philadelphia, ⁵University of Pennsylvania and Corporal Michael J. Crescenz Veterans Administration Hospital, Philadelphia
Background/Purpose: Cutaneous Lupus Erythematosus (CLE) is an autoimmune skin disease that may occur with or without systemic lupus erythematosus (SLE). Active CLE lesions present with…
Abstract Number: 0021 • ACR Convergence 2020
Prioritizing Patient Safety While Maintaining Study Integrity During COVID-19: Lupus Intervention Fatigue Trial Modifications and Lessons Learned
Dominique Kinnett-Hopkins¹, Linda Ehrlich-Jones², Holly Milaeger³, Alanna Kenney³, Lorena Rosiles³ and Rosalind Ramsey-Goldman⁴, ¹Northwestern University, Chicago, IL, ²Shirley Ryan AbilityLab, Chicago, ³Northwestern University, Chicago, ⁴Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: The coronavirus disease 2019 (COVID-19) global pandemic has drastically impacted the health system and the research community. Many research institutions and funding agencies recommended…
Abstract Number: 0253 • ACR Convergence 2020
Serum Albumin as a Predictor of Proteinuria Recovery in Lupus Nephritis
Tara Tofighi¹, Heather Reich², Jiandong Su³ and Zahi Touma⁴, ¹Department of Medicine, University of Toronto, Toronto, Canada, ²Division of Nephrology, University of Toronto, Toronto, Canada, ³University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁴University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network; Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Clinical trials and observational studies in lupus nephritis (LN) have shown that proteinuria level at 12 months is the best predictor of long-term renal…
Abstract Number: 0270 • ACR Convergence 2020
The New EULAR/ ACR 2019 SLE Classification Criteria: Defining Ominosity in SLE
Laura Whittall-Garcia¹, Dafna Gladman², Murray Urowitz³, Jiandong Su⁴ and Sindhu Johnson⁵, ¹University Health Network, Toronto, ON, Canada, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: SLE is characterized by different patterns of disease activity throughout its course. Overall, a higher disease activity is an important predictor of mortality and…
Abstract Number: 0287 • ACR Convergence 2020
RNA Externalized by Neutrophil Extracellular Traps Promotes Inflammatory Pathways in Endothelial Cells
Xinghao Wang¹, Philip Carlucci², Jorge Romo-Tena¹, Jose Torres-Ruiz¹, Hong-Wei Sun¹, Markus Hafner¹, Mariana Kaplan³ and Luz Blanco⁴, ¹NIAMS, National Institute of Health, Bethesda, ²New York University School of Medicine, New York, NY, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, Centreville
Background/Purpose: Neutrophil extracellular traps (NETs) are extracellular lattices composed of nucleic material bound to neutrophil granule proteins. NETs may play pathogenic roles in development and…
Abstract Number: 0304 • ACR Convergence 2020
Type I Interferon Inhibits Glucocorticoid-Induced Leucine Zipper (GILZ) Expression and Upregulation by Glucocorticoids
Wendy Dankers¹, Melissa Northcott², Taylah Bennett³, Brendan Russ³, Jacqueline Flynn¹, Sarah Jones² and Eric Morand¹, ¹Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ²Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia, ³Department of Microbiology, Monash University, Melbourne, Australia
Background/Purpose: Glucocorticoids (GC) are broadly used in the treatment of inflammatory diseases, including systemic lupus erythematosus (SLE). Despite their widespread use, most SLE patients do…
Abstract Number: 0521 • ACR Convergence 2020
Avoiding Misclassification of Primary Antiphospholipid Syndrome as Systemic Lupus Erythematosus: What Are the Best-performing SLE Classification Criteria?
Flavio Signorelli¹, Gustavo Balbi², Eloisa Bonfa³, Eduardo Borba⁴ and Danieli Andrade⁵, ¹Universidade de São Paulo, Rio de janeiro, Rio de Janeiro, Brazil, ²Universidade de São Paulo, Juiz de Fora, Minas Gerais, Brazil, ³Hospital das Clínicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Sao Paulo, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁵University of Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Primary Antiphospholipid Syndrome (PAPS) patients, when submitted to Systemic Lupus Erythematosus (SLE) classification criteria, can be misclassified. The new 2019 ACR/EULAR classification criteria have…
Abstract Number: 0788 • ACR Convergence 2020
Rigorous Plasma Microbiome Analysis Method Enables Disease Association Discovery
Wei Jiang¹, Alexander Alekseyenko², Gary Gilkeson³, Jim Oates⁴, Elizabeth Ogunrind⁵, Quan Li⁶, Diane Kamen², Betty Tsao⁵ and Zhenwu Luo⁵, ¹MUSC, Charleston, SC, ²Medical University of South Carolina, Charleston, SC, ³Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁴Medical University of South Carolina, Charleston, SC, Charleston, SC, ⁵Medical University of South Carolina, Charleston, ⁶UT South Western Medical Center, Texas
Background/Purpose: The mucosal microbiome contributes to disease pathogenesis via local and systemic interaction with the host. The hallmark of this interaction in the physiological condition…
Abstract Number: 0855 • ACR Convergence 2020
Treatment of SLE with or Without Nephritis with the Immunoproteasome Inhibitor KZR-616: Updated Results of the MISSION Study
Richard Furie¹, Samir Parikh², Kenneth Harvey³, Christopher Kirk⁴, Darrin Bomba⁴ and MK Farmer⁵, ¹Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²The Ohio State University, Columbus, OH, ³Kezar Life Sciences, South San Francisco, CA, ⁴Kezar Life Sciences, Inc, San Francisco, CA, ⁵Kezar, Raleigh, NC
Background/Purpose: Immunoproteasome inhibition has demonstrated meaningful therapeutic potential in preclinical models of systemic lupus erythematosus (SLE) and lupus nephritis (LN). KZR-616 is a first-in-class selective…
Abstract Number: 0887 • ACR Convergence 2020
Increasing Use of Biologics in Treatment of Systemic Lupus Erythematosus Patients in US Clinical Practice: Real-World Observations from Trio Health and the American Rheumatology Network
Simon Helfgott¹, Jeremy Broestl², Kent Kwas Huston³, Deepali Rane², Jasvinder Singh⁴, Nehad Soloman⁵ and Colin Edgerton⁶, ¹BWH- HMS, Boston, MA, ²Trio Health, Louisville, CO, ³Kansas City Physician Partners, Kansas City, MO, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ⁶Articularis Healthcare, Summerville, SC
Background/Purpose: Systemic lupus erythematosus (SLE) treatments include steroids, antimalarials, immunosuppressants and/or biologics, though the use of biologics has been reported as minimal in claim-based studies…
Abstract Number: 0990 • ACR Convergence 2020
Interferon Lambda Promotes Human Plasma Cell Differentiation in Lupus and Healthy Donors
Jennifer Barnas¹, Jennifer Albrecht¹ and Jennifer Anolik¹, ¹University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by antinuclear autoantibodies produced by plasma cells. Type I interferon (IFN) are cytokines which…
Abstract Number: 1143 • ACR Convergence 2020
The Influence of YouTube on Spreading Awareness and Patient Education Regarding Systemic Lupus Erythematosus
Priyatha Garlapati¹, Jasmeen Uppal¹, Sarwat Umer² and Samina Hayat², ¹LSU Shreveport, Shreveport, ²LSU Shreveport, Shreveport, LA
Background/Purpose: A large global survey released by the World Lupus Federation showed that the awareness of SLE is low and many individuals have never heard…
Abstract Number: 1270 • ACR Convergence 2020
Trend of Survival of a Cohort of Patients with Systemic Lupus Erythematosus over 25 Years
Chi Chiu Mok¹, Ling Yin Ho¹, Kar Li Chan², Sau Mei Tse² and Chi Hung To³, ¹Tuen Mun Hospital, Hong Kong, China (People's Republic), ²Tuen Mun Hospital, Hong Kong, Hong Kong, ³Pok Oi Hospital, Hong Kong, Hong Kong
Background/Purpose: Background: Few studies of systemic lupus erythematosus (SLE) have a follow-up duration long enough to evaluate the time trend of survival, particularly in Asian…
Abstract Number: 1286 • ACR Convergence 2020
Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus by Physician Global Assessment of Disease Activity
May Choi¹, Emma Stevens², Hongshu Guan², Daniel Li³, Jack Ellrodt⁴, Benjamin Kargere⁴, Tianrun Cai², Kazuki Yoshida⁵, Brendan Everett² and Karen Costenbader⁶, ¹Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Brigham and Women's Hospital, Boston, MA, ³Harvard, Columbus, OH, ⁴Williams College, Williamstown, ⁵Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: The risk of cardiovascular disease (CVD), including myocardial infarction and stroke, is higher in SLE than in the general population. The excess risk of…
Abstract Number: 1302 • ACR Convergence 2020
Exploration of Machine Learning Methods in Predicting Systemic Lupus Erythematosus Hospitalizations
April Jorge¹, Zhiyao Wu², Tashrif Chowdhury² and Yijun Zhao², ¹Massachusetts General Hospital, Boston, MA, ²Fordham University, Computer and Information Sciences Department, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous disease associated with increased morbidity and mortality, and severe SLE flares can lead to hospitalizations. Our objective…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].